Role of phosphatidylinositol signaling pathway in the development of cross-resistance of tumor cells to hormonal cytostatics and hypoxia

被引:0
|
作者
Shatskaya, V. A. [1 ]
Pavlichenko, O. V. [1 ]
Krasil'nikov, M. A. [1 ]
机构
[1] Russian Acad Med Sci, NN Blokhin Res Canc Res Ctr, Moscow 109801, Russia
基金
俄罗斯基础研究基金会;
关键词
ovarian adenocarcinoma; dexamethasone; hypoxia; phosphatidylinositol; 3-kinase; proliferation;
D O I
10.1007/s10517-007-0061-7
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Long-term in vitro culturing of CaOv ovarian adenocarcinoma cells in the presence of a synthetic analogue of glucocorticoid hormone dexamethasone allowed us to obtain a subline of CaOv/D cells resistant to the antiproliferative effect of dexamethasone and characterized by high resistance to hypoxia. It was found that CaOv/D cells are characterized by constitutive increase in phosphatidylinositol 3-kinase expression and hypersecretion of vascular endothelial growth factor VEGF-A. Culturing of cells under hypoxic conditions was accompanied by a significant increase in phosphatidylinositol 3-kinase expression and VEGF-A synthesis. Experiments with cell transfection with phosphatidylinositol 3-kinase catalytic subunit proved its participation in the regulation of VEGF-A synthesis and maintenance of cell growth under condition of hypoxia. Our results indicate that coordinated activation of phosphatidylinositol 3-kinase and VEGF-A can be a factor determining the development of cross-resistance of tumor cells to hormonal cytostatics and hypoxia.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 50 条
  • [1] Role of phosphatidylinositol signaling pathway in the development of cross-resistance of tumor cells to hormonal cytostatics and hypoxia
    V. A. Shatskaya
    O. V. Pavlichenko
    M. A. Krasil’nikov
    Bulletin of Experimental Biology and Medicine, 2007, 143 : 244 - 247
  • [2] Increased resistance to hypoxia in hormone-insensitive tumor cells: the role of phosphatidylinositol-3 kinase signaling pathway
    Krasil'nikov, MA
    Pavlichenko, OV
    Shatskaya, VA
    BIOLOGICHESKIE MEMBRANY, 2003, 20 (02): : 135 - 141
  • [3] DEVELOPMENT OF RESISTANCE AND CROSS-RESISTANCE IN THE CHLOROETHYLNITROSOUREA CHEMOTHERAPY OF BRAIN-TUMOR CELLS
    MINEURA, K
    IZUMI, I
    WATANABE, K
    KOWADA, M
    FASEB JOURNAL, 1993, 7 (04): : A690 - A690
  • [4] CROSS-RESISTANCE TO CYTOSTATICS OF P388 LEUKEMIA-CELLS WITH INDUCED RESISTANCE TO DOXORUBICIN
    DONENKO, FV
    SITDIKOVA, SM
    KABIEVA, AO
    MOROZ, LV
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 1993, 116 (09) : 1153 - 1155
  • [5] Cross-resistance and sensitivity of sunitinib resistant tumor cells
    Gotink, Kristy J.
    Broxterman, Henk J.
    de Haas, Richard R.
    Rovithi, Maria N.
    Pili, Roberto
    Verheul, Henk M. W.
    CANCER RESEARCH, 2012, 72
  • [6] The Wnt signaling pathway and its role in tumor development
    B. Lustig
    J. Behrens
    Journal of Cancer Research and Clinical Oncology, 2003, 129 : 199 - 221
  • [7] The Wnt signaling pathway and its role in tumor development
    Lustig, B
    Behrens, J
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (04) : 199 - 221
  • [8] Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells
    Gao, ZQ
    Gao, ZP
    Fields, JZ
    Boman, BM
    ANTICANCER RESEARCH, 2002, 22 (03) : 1379 - 1383
  • [9] Cross-resistance of tumor cells to chemotherapy and immunotherapy: Approaches to reverse resistance and implications in gene therapy (review)
    Bonavida, B
    Safrit, J
    Morimoto, H
    Mizutani, Y
    Uslu, R
    Borsellino, N
    Frost, P
    Berek, J
    Belldegrun, A
    Zighelboim, J
    Ng, CP
    Mori, S
    ONCOLOGY REPORTS, 1997, 4 : 201 - 205
  • [10] The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells
    Nakamura, Tomoyuki
    Tanaka, Kazuhiro
    Matsunobu, Tomoya
    Okada, Takamitsu
    Nakatani, Fumihiko
    Sakimura, Riku
    Hanada, Masuo
    Iwamoto, Yukihide
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 31 (04) : 803 - 811